<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158950</url>
  </required_header>
  <id_info>
    <org_study_id>2009-12-461</org_study_id>
    <secondary_id>W81XWH-10-1-0231</secondary_id>
    <nct_id>NCT01158950</nct_id>
  </id_info>
  <brief_title>A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors</brief_title>
  <official_title>A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Berkeley</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we seek to understand the effects of tolcapone, an FDA-approved COMT&#xD;
      inhibitor, on reward choice and response inhibition, two measures we have previously shown to&#xD;
      be altered in subjects with alcoholism. We now plan to test the hypothesis that COMT&#xD;
      regulation of cortical dopamine levels is critical for regulation financial choices.&#xD;
      Specifically, we propose that the lower levels of cortical dopamine present in individuals&#xD;
      with the val158val COMT genotype reduces the inhibitory effect of frontal cortical areas on&#xD;
      impulsive choice; an idea that extends previous hypotheses about the negative consequences of&#xD;
      decreased prefrontal dopamine levels on inhibitory control. Moreover, this hypothesis&#xD;
      suggests that inhibiting COMT may slow the degradation of dopamine and thereby decrease&#xD;
      impulsivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug consumption despite adverse consequences is a defining feature of human addiction&#xD;
      (DSM-IV-TR, 2004). Impulsivity, a tendency to choose an immediate action despite delayed&#xD;
      adverse consequences, is a major risk factor for tobacco, psychostimulant, opioid and alcohol&#xD;
      abuse. In humans, impulsivity can be quantified by presenting subjects with a choice between&#xD;
      a small immediate monetary reward or a larger but delayed reward. We recently found that the&#xD;
      val158val allele for the enzyme catechol-O-methyltransferase (COMT), which is associated with&#xD;
      more rapid cortical dopamine catabolism and thus lower cortical dopamine levels correlates&#xD;
      with greater impulsivity and greater fMRI blood oxygen level dependent (BOLD) signal in&#xD;
      dorsolateral prefrontal and posterior parietal cortices.&#xD;
&#xD;
      The first phase of the study will involve healthy controls. The second phase of the study&#xD;
      will involve abstinent alcoholics matched for age, education, and gender. Subjects will range&#xD;
      in age between 18 and 50 years old.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale</measure>
    <time_frame>120 minutes after drug ingestion</time_frame>
    <description>The presented value represents a correlation. Subjects completed a delay discounting task while functional MRI images were obtained. In this task, subjects made hypothetical choices between a smaller amount of money available sooner, and a larger amount of money available later. Performance on the delay discounting task, as assessed by the impulsive choice ratio, was determined for both the tolcapone and placebo sessions, and the difference between them (tolcapone minus placebo) was calculated. This difference value was then correlated with baseline scores on the Barratt Impulsiveness Scale.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Correlation Between the Difference in ICR (Tolcapone Minus Placebo) and the Difference in Blood Oxygen Level Dependent (BOLD) Signal in the Brain (Tolcapone Minus Placebo)</measure>
    <time_frame>120 minutes after drug ingestion</time_frame>
    <description>The presented value represents a correlation. The difference in performance on the delay discounting task was calculated as the change in ICR (tolcapone minus placebo). In addition, the difference in BOLD activity throughout the brain was determined (tolcapone minus placebo).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Impulsive Behavior</condition>
  <arm_group>
    <arm_group_label>Tolcapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Tolcapone 200mg (single dose) administered at study visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo for tolcapone administered at study visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>Drug: Tolcapone 200mg (single dose) administered at study visit</description>
    <arm_group_label>Tolcapone</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (200mg) administered at study visit</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 50 years.&#xD;
&#xD;
          -  Subject is right-handed.&#xD;
&#xD;
          -  If female, subject is non-lactating, not pregnant, and using a reliable contraception&#xD;
             method (i.e. abstinence, intrauterine device (IUD), hormonal birth control or barrier&#xD;
             method).&#xD;
&#xD;
          -  Subject is able to read and speak English.&#xD;
&#xD;
          -  Subject is a high school graduate.&#xD;
&#xD;
          -  Subject is able and willing to provide written and informed consent.&#xD;
&#xD;
          -  Subject is able to understand and follow the instructions of the investigator, and&#xD;
             understand all ratings scales.&#xD;
&#xD;
          -  Subject is in good health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Using cocaine, stimulants (other than THC, nicotine, &amp; caffeine)amphetamines,&#xD;
             hallucinogens, &quot;ecstasy&quot;, opiates, sedatives, pain pills, sleeping pills or other&#xD;
             psychoactive drugs within two weeks of the start of the study OR more than 10 times in&#xD;
             the last year.&#xD;
&#xD;
          -  Has a current dependence on, or addiction to any psychoactive drug (except nicotine or&#xD;
             caffeine) including alcohol.&#xD;
&#xD;
          -  Clinically significant medical or psychiatric illness requiring treatment as&#xD;
             determined by screening blood tests, medical history, and physical exam performed or&#xD;
             reviewed by the study physician.&#xD;
&#xD;
          -  Subject has a history of major alcohol related complications within the proceeding 2&#xD;
             years (liver failure/cirrhosis, pancreatitis, esophageal varices, etc.)&#xD;
&#xD;
          -  Liver function test â‰¥ 3 times normal upper limit.&#xD;
&#xD;
          -  BAC level &gt; 0.05% at the beginning of screening visit (within margin of error of&#xD;
             detection).&#xD;
&#xD;
          -  Has a neurological dysfunction or psychiatric disorder.&#xD;
&#xD;
          -  Has severe low blood pressure.&#xD;
&#xD;
          -  Has uncontrolled high blood pressure.&#xD;
&#xD;
          -  Regular use of any of the drugs on the tolcapone or entacapone contraindications list&#xD;
             OR within 2 weeks of drug administration.&#xD;
&#xD;
          -  Regular use of SSRIs.&#xD;
&#xD;
          -  Has an allergy or intolerance to tolcapone or entacapone.&#xD;
&#xD;
          -  Subject has received an investigational drug within 30 days of screening visit.&#xD;
&#xD;
          -  Subject is considered unsuitable for the study in the opinion of the investigator or&#xD;
             study physician for any other reason.&#xD;
&#xD;
        MRI Exclusion Criteria:&#xD;
&#xD;
          -  The subject has metal (metal plates, pins, wires or screws, artificial limb, joint&#xD;
             replacement or anything that might have been inserted during an operation) in his/her&#xD;
             body.&#xD;
&#xD;
          -  Subject has a pacemaker, defibrillator, stent, or any metal implants related to&#xD;
             heart/blood flow problems.&#xD;
&#xD;
          -  Subject has worked with metals (ie. metallurgy, metal shaving, welding, soldering,&#xD;
             etc).&#xD;
&#xD;
          -  Subject has been wounded with anything metal (bullet, shrapnel or metal filling).&#xD;
&#xD;
          -  Has ever gotten a piece of metal in the eye.&#xD;
&#xD;
          -  Has tattoos done with ink containing metal or permanent eyeliner.&#xD;
&#xD;
          -  Wears color contact lenses.&#xD;
&#xD;
          -  Has a hearing problem or hearing aid, cochlear implant or past ear surgery.&#xD;
&#xD;
          -  Has any irremovable dental bridges, dental plates, metal caps or any other&#xD;
             non-removable metal in the mouth.&#xD;
&#xD;
          -  The subject is claustrophobic.&#xD;
&#xD;
          -  The subject is pregnant. (women only)&#xD;
&#xD;
          -  Has a IUD. (women only)&#xD;
&#xD;
          -  Significantly overweight.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Fields, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF: Ernest Gallo Clinic and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Mitchell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UCSF: Ernest Gallo Clinic and Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Berkeley</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF: Ernest Gallo Clinic and Research Center</name>
      <address>
        <city>Emeryville</city>
        <state>California</state>
        <zip>94591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL. Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci. 2012 Jul 4;32(27):9402-9. doi: 10.1523/JNEUROSCI.1180-12.2012.</citation>
    <PMID>22764248</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Impulsive Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 4, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT01158950/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects were screened for inclusion / exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tolcapone First, Then Placebo</title>
          <description>Tolcapone 200mg (single dose) then Placebo (single dose) administered at study visit, followed by crossover to other drug at next visit</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Tolcapone</title>
          <description>Placebo (single dose) then Tolcapone 200mg (single dose) tadministered at study visit, followed by crossover to other drug at next visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>1st Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Data Collected</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2nd Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants receiving either Tolcapone 200mg (single dose) or Placebo (single dose) administered at study visit, followed by crossover to other drug at next visit - all participants were randomized to receive all interventions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Barratt Impulsiveness Scale</title>
          <description>The Barratt Impulsiveness Scale measures impulsive behavior on a 20-80 point scale, with higher numbers corresponding to greater impulsivity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale</title>
        <description>The presented value represents a correlation. Subjects completed a delay discounting task while functional MRI images were obtained. In this task, subjects made hypothetical choices between a smaller amount of money available sooner, and a larger amount of money available later. Performance on the delay discounting task, as assessed by the impulsive choice ratio, was determined for both the tolcapone and placebo sessions, and the difference between them (tolcapone minus placebo) was calculated. This difference value was then correlated with baseline scores on the Barratt Impulsiveness Scale.</description>
        <time_frame>120 minutes after drug ingestion</time_frame>
        <population>The outcome for this study was the correlation between the baseline BIS score and the difference in ICR (tolcapone minus placebo). As such, one Arm/Group is presented below.</population>
        <group_list>
          <group group_id="O1">
            <title>Functional MRI Arm (Tolcapone and Placebo)</title>
            <description>This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion. Tolcapone is a medication in the class of catechol-O-methyltransferase (COMT) inhibitors. A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between the Impulsive Choice Ratio and Baseline Impulsivity, as Measured With the Barratt Impulsiveness Scale</title>
          <description>The presented value represents a correlation. Subjects completed a delay discounting task while functional MRI images were obtained. In this task, subjects made hypothetical choices between a smaller amount of money available sooner, and a larger amount of money available later. Performance on the delay discounting task, as assessed by the impulsive choice ratio, was determined for both the tolcapone and placebo sessions, and the difference between them (tolcapone minus placebo) was calculated. This difference value was then correlated with baseline scores on the Barratt Impulsiveness Scale.</description>
          <population>The outcome for this study was the correlation between the baseline BIS score and the difference in ICR (tolcapone minus placebo). As such, one Arm/Group is presented below.</population>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The comparison group represents the difference in ICR and the baseline impulsiveness scale.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <p_value_desc>The threshold for statistical significance was set to p &lt; 0.05.</p_value_desc>
            <method>Fisher transformation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation Between the Difference in ICR (Tolcapone Minus Placebo) and the Difference in Blood Oxygen Level Dependent (BOLD) Signal in the Brain (Tolcapone Minus Placebo)</title>
        <description>The presented value represents a correlation. The difference in performance on the delay discounting task was calculated as the change in ICR (tolcapone minus placebo). In addition, the difference in BOLD activity throughout the brain was determined (tolcapone minus placebo).</description>
        <time_frame>120 minutes after drug ingestion</time_frame>
        <population>The outcome for this study was the correlation between the difference in the ICR and the difference in BOLD activity (tolcapone minus placebo). As such, one Arm / Group is presented below.</population>
        <group_list>
          <group group_id="O1">
            <title>Functional MRI Arm (Tolcapone and Placebo)</title>
            <description>This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion. Tolcapone is a medication in the class of catechol-O-methyltransferase (COMT) inhibitors. A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between the Difference in ICR (Tolcapone Minus Placebo) and the Difference in Blood Oxygen Level Dependent (BOLD) Signal in the Brain (Tolcapone Minus Placebo)</title>
          <description>The presented value represents a correlation. The difference in performance on the delay discounting task was calculated as the change in ICR (tolcapone minus placebo). In addition, the difference in BOLD activity throughout the brain was determined (tolcapone minus placebo).</description>
          <population>The outcome for this study was the correlation between the difference in the ICR and the difference in BOLD activity (tolcapone minus placebo). As such, one Arm / Group is presented below.</population>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.05</p_value>
            <p_value_desc>The threshold is set to p &lt; 0.05, corrected for multiple comparisons.</p_value_desc>
            <method>Fisher transformation</method>
            <method_desc>Statistical tests are computed across multiple subregions (voxels) within each area. Thus, the correlation coefficient above is a summary score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tolcapone</title>
          <description>Tolcapone 200mg (single dose)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (single dose)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Funding constrained the number of participants. Describing the thousands of statistical tests in neuroimaging studies is not possible within this reduced format. Please see the open access pdf of Kayser et al, JNeurocience 2012.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Mitchell</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>510-985-3522</phone>
      <email>jennifer.mitchell@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

